Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Chief Business Officer | December 10, 2021 | December 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date December 10, 2021 · Filed December 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,696 |
Ending reported balance
After 2021-12-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-12-10 · Exercise / conversion · Acquired 1,500 · Balance 15,062 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Row 2 · 2021-12-10 · Tax withholding · Disposed 366 · Balance 14,696 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,500 |
Reported balance
After 2021-12-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-10 · Exercise / conversion · Disposed 1,500 · Balance 4,500 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 15, 2021 01:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000270 · wf-form4_163952998240535.xml · derivative · entry 3 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021. F2 · derivative.expiration_date: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 366 | $40.52 | $14,830.32 |
DisclosureSEC source: 0001447362-21-000270 · wf-form4_163952998240535.xml · nonDerivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,696 Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-21-000270 · wf-form4_163952998240535.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 6,412 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · derivative · entry 7 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,304 Underlying: Common Stock · 6,412 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. F6 · derivative.exercise_date: 25% of the 12,305 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 8,989 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · derivative · entry 6 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,889 Underlying: Common Stock · 8,989 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. F5 · derivative.exercise_date: 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,474 | $77.29 | $113,925.46 |
DisclosureSEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 5 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,562 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $76.70 to $77.63, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,889 | $76.14 | $448,388.46 |
DisclosureSEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 4 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,036 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $75.60 to $76.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,038 | $75.24 | $604,779.12 |
DisclosureSEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 3 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,925 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.59 to $75.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 6,412 | $2.39 | $15,324.68 |
DisclosureSEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:26 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 8,989 | $1.92 | $17,258.88 |
DisclosureSEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 8,989 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001447362-21-000130 · wf-form4_162335918644795.xml · derivative · entry 3 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,878 Underlying: Common Stock · 8,989 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 24, 2021. F3 · derivative.exercise_date: 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,989 | $70.00 | $629,230.00 |
DisclosureSEC source: 0001447362-21-000130 · wf-form4_162335918644795.xml · nonDerivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,562 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 24, 2021. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 8,989 | $1.92 | $17,258.88 |
DisclosureSEC source: 0001447362-21-000130 · wf-form4_162335918644795.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 24, 2021. F2 · balance_after: Includes 1,815 shares acquired on February 26, 2021 under the Issuer's employee stock purchase plan. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 19:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-20-000289 · wf-form4_160797283348524.xml · derivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on December 10, 2021. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on December 10, 2021. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 19:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 23,000 | $0.00 Strike: $59.16 | $0.00 |
DisclosureSEC source: 0001447362-20-000289 · wf-form4_160797283348524.xml · derivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-12-09 F1 · derivative.exercise_date: 25% of shares shall vest on December 10, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 40,000 | $49.97 | $1,998,800.00 |
DisclosureSEC source: 0001447362-20-000270 · wf-form4_160702964050490.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,747 F1 · price: This transaction was executed in multiple trades at prices ranging from $49.68 to $50.08, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 15,000 | $49.80 | $747,000.00 |
DisclosureSEC source: 0001447362-20-000213 · wf-form4_159976867970562.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,747 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 20:03 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 14,888 | $49.00 | $729,512.00 |
DisclosureSEC source: 0001447362-20-000207 · wf-form4_159968177654132.xml · nonDerivative · entry 3 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,747 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 20:03 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,112 | $49.00 | $250,488.00 |
DisclosureSEC source: 0001447362-20-000207 · wf-form4_159968177654132.xml · nonDerivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,635 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 20:03 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 20,000 | $47.00 | $940,000.00 |
DisclosureSEC source: 0001447362-20-000207 · wf-form4_159968177654132.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,747 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020. F2 · balance_after: Includes 1,121 shares acquired under the Issuer's employee stock purchase plan on August 31, 2020. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 20,000 | $45.00 | $900,000.00 |
DisclosureSEC source: 0001447362-20-000189 · wf-form4_159804042475133.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,626 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 400 | $38.94 | $15,576.00 |
DisclosureSEC source: 0001447362-20-000101 · wf-form4_159130122788334.xml · nonDerivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,626 F2 · price: This transaction was executed in multiple trades at prices ranging from $38.93 to $38.95, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 31,833 | $38.18 | $1,215,383.94 |
DisclosureSEC source: 0001447362-20-000101 · wf-form4_159130122788334.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,026 F1 · price: This transaction was executed in multiple trades at prices ranging from $37.93 to $38.92, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 32,233 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001447362-20-000055 · wf-form4_158931513579119.xml · derivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,867 Underlying: Common Stock · 32,233 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:25 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 32,233 | $1.92 | $61,887.36 |
DisclosureSEC source: 0001447362-20-000055 · wf-form4_158931513579119.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $29.50 | $0.00 |
DisclosureSEC source: 0001447362-19-000024 · wf-form4_157661715881831.xml · derivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: 25% of the shares shall vest on December 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:24 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionConvertible Promissory Note · Derivative | Not disclosed | Not disclosed Strike: $12.80 | $20,000.00 |
DisclosureSEC source: 0001209191-19-043858 · doc4.xml · derivative · entry 4 Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,619 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F2 · reported_value: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F2 · price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F2 · derivative.exercise_date: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F2 · derivative.expiration_date: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:24 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries F Preferred Stock · Derivative | 6,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043858 · doc4.xml · derivative · entry 3 Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F1 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:24 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionCommon Stock | 1,619 | $12.80 | $20,723.20 |
DisclosureSEC source: 0001209191-19-043858 · doc4.xml · nonDerivative · entry 2 Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:24 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionCommon Stock | 5,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043858 · doc4.xml · nonDerivative · entry 1 Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.